Recombinant Human LDLR Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

The low density lipoprotein receptor (LDL R) is the founding member of the LDL R family of widely expressed cell surface scavenger receptors (1-5). Members of the family are endocytic receptors, but can also co-regulate adjacent cell-surface signaling molecules (3, 4). Many proteins in the LDL R family are cleaved by extracellular proteases to release soluble forms to the circulation, and many of these soluble forms are active (1, 6). Mature LDL R is a 120-160 kDa (depending on glycosylation) type I transmembrane glycoprotein that contains cysteine-rich complement-like repeats (class A LDL domains), calcium-binding EGF repeats, and beta ‑propeller structures (class B LDL repeats) in the extracellular domain (ECD) (1-7). A membrane-proximal Ser/Thr-rich region shows extensive O-linked glycosylation (4, 8). A cytoplasmic NPxY motif links the LDL R to clathrin pits for endocytosis, and binds to select adaptor proteins (1, 4, 8). The human LDL R ECD shares 78%, 76%, 81% and 82% aa sequence identity with mouse, rat, bovine, and porcine LDL R, respectively. LDL R is constitutively and widely expressed. Its class A LDL domains near the N-terminus bind apoB and apoE, the apolipoproteins of low- and very low-density lipoproteins (LDL and VLDL), respectively (1, 2, 4, 9). Hepatocyte LDL R is responsible for endocytosis and clearing of most plasma LDL cholesterol (2, 9). At the low pH of the endocytic vesicle, it dissociates, allowing degradation of LDL and recycling of LDL R to the cell surface (1, 4).  Lack of LDL R expression or function causes familial hypercholesterolemia (FH) (4, 9, 10). The protease PCSK9 (proprotein convertase subtilisin/kexin type 9) can also cause increased plasma cholesterol by promoting LDL R degradation rather than recycling to the cell surface (10-12). Soluble forms of approximately 140 kDa and 28 kDa are reported to be released by phorbol esters or interferons, respectively (6, 7)

We have publications tested in 2 confirmed species: Human, Hamster.

We have publications tested in 4 applications: Binding Assay, Bioassay, Surface Plasmon Resonance, TR-FRET.

Showing Publications 1 - 8 of 8.

Publications using 2148-LD/CF	Applications	Species
Y Masuda, S Yamaguchi, C Suzuki, T Aburatani, Y Nagano, R Miyauchi, E Suzuki, N Yamamura, K Nagatomo, H Ishihara, K Okuno, F Nara, G Matschiner, R Hashimoto, T Takahashi, T Nishizawa Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein J. Pharmacol. Exp. Ther., 2018-02-20;365(2):368-378. 2018-02-20 [PMID: 29463608] (Bioassay, Human)	Bioassay	Human
SA Felt, GN Droby, VZ Grdzelishv Ruxolitinib and polycation combination treatment overcomes multiple mechanisms of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus J. Virol., 2017-07-27;0(0):. 2017-07-27 [PMID: 28566376] (Bioassay, Human)	Bioassay	Human
Amirache F, Levy C, Costa C, Mangeot P, Torbett B, Wang C, Negre D, Cosset F, Verhoeyen E Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor. Blood, 2014-02-27;123(9):1422-4. 2014-02-27 [PMID: 24578496] (Bioassay, Human)	Bioassay	Human
Kurasawa J, Shestopal S, Karnaukhova E, Struble E, Lee T, Sarafanov A Mapping the binding region on the low density lipoprotein receptor for blood coagulation factor VIII. J Biol Chem, 2013-06-10;288(30):22033-41. 2013-06-10 [PMID: 23754288] (Binding Assay, Human)	Binding Assay	Human
DeVay , Rachel M, Shelton , David L, Liang , Hong Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). J Biol Chem, 2013-02-19;288(15):10805-18. 2013-02-19 [PMID: 23430252] (Bioassay, Human)	Bioassay	Human
Duff CJ, Scott MJ, Kirby IT, Hutchinson SE, Martin SL, Hooper NM Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem. J., 2009-05-01;419(3):577-84. 2009-05-01 [PMID: 19196236] (Surface Plasmon Resonance, Human)	Surface Plasmon Resonance	Human
Chien YJ, Chen WJ, Hsu WL, Chiou SS Bovine lactoferrin inhibits Japanese encephalitis virus by binding to heparan sulfate and receptor for low density lipoprotein. Virology, 2008-07-21;379(1):143-51. 2008-07-21 [PMID: 18640695] (Bioassay, Hamster)	Bioassay	Hamster
Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, Cummings RT, Calzetta A, Cubbon RM, Fischer PA, Tarachandani A, De Francesco R, Wright SD, Sparrow CP, Carfi A, Sitlani A Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J. Biol. Chem., 2007-05-10;282(28):20502-12. 2007-05-10 [PMID: 17493938] (Surface Plasmon Resonance, TR-FRET, Human)	Surface Plasmon Resonance, TR-FRET	Human

Array 2148-LD/CF

• LDLR Antibodies
• LDLR Antibody Pair
• LDLR ELISA Kit
• LDLR Lysate
• LDLR Proteins
• LDLR Proteins and Enzymes
• LDLR ELISAs